CAJ | 학술논문

目的：探讨DNA修复相关基因ERCC1与BRCA1在非小细胞肺癌化疗耐药中的作用。方法选取70例非小细胞肺癌化疗患者为研究对象，按照化疗药物耐药试验分为耐药组（30例）和敏感组（40例），采取免疫组织化学法检测两组患者ERCC1、BRCA1的表达情况。结果耐药组ERCC1、BRCA1阳性率分别为83．3％、80．0％；敏感组ERCC1、BRCA1阳性率分别为32．5％、35．0％；耐药组ERCC1、BRCA1阳性率均明显高于敏感组（ P＜0．05）。结论 DNA修复相关基因ERCC1与BRCA1在非小细胞肺癌化疗耐药患者中异常表达，临床中可以依据其表达情况指导用药。
목적：탐토DNA수복상관기인ERCC1여BRCA1재비소세포폐암화료내약중적작용。방법선취70례비소세포폐암화료환자위연구대상，안조화료약물내약시험분위내약조（30례）화민감조（40례），채취면역조직화학법검측량조환자ERCC1、BRCA1적표체정황。결과내약조ERCC1、BRCA1양성솔분별위83．3％、80．0％；민감조ERCC1、BRCA1양성솔분별위32．5％、35．0％；내약조ERCC1、BRCA1양성솔균명현고우민감조（ P＜0．05）。결론 DNA수복상관기인ERCC1여BRCA1재비소세포폐암화료내약환자중이상표체，림상중가이의거기표체정황지도용약。
Objective To investigate the role of DNA repair-related genes ERCC1 and BRCC1 in chemotherapy resistance of non-small cell lung cancer (NSCLC).Methods According to the degree of chemotherapy resistance ,70 NSCLC patients were divided into resistant group (30 cases) and sensitive group (40 cases),immunohistochemistry method was used to detect the expressions of ERCC1 and BRCA1 in both groups.Results The positive rates of ERCC1 and BRCA1 of resistant group were 83.3%and 80.0%,respectively,while of sensitive group were 32.5%and 35.0%,respectively.The positive rates of ERCC1 and BRCA1 of resistant group were significantly higher than those of sensitive group (P<0.05). Conclusion The expressions of DNA repair-related genes ERCC1, BRCC1 are abnormal in chemotherapy resistance of NSCLC patients,and the clinical medication can be instructed according to the expressions of ERCC 1 and BRCC1.